Who Attended in 2023:
Thank You to Our Speakers, Sponsors, and Delegates Who Joined Us in June for the Summit! If You Are Interested in the 2024 Event, Please Get in Touch by Clicking the Button Below:
Innovating Imaging Measures of Disease Progression & Improvement to Determine Drug Efficacy Sooner
June 13 - 15, Boston MA
Welcome to the Definitive Industry Forum for Advancing Imaging Biomarkers to Accelerate Retinal Drug Development
Uniting biotech and pharma scientists to revolutionize ophthalmic drug development, the Retinal Imaging Biomarkers & Endpoints Summit encouraged forward-thinking discussions to enhance the adoption of novel imaging-based approaches to determine retinal function and optimize development of regulatory accepted endpoints.
60+ retinal imaging, innovation, R&D, preclinical and clinical experts from the likes of Genentech, AbbVie, Apellis, Janssen and Novartis came together to overcome the translational challenges of choosing and implementing novel ophthalmic imaging biomarkers and endpoints in your research, to accelerate earlier, non-invasive and personalised healthcare for ophthalmic and neurodegenerative patients.
A Snapshot of 2023’s World-Class Speaker Faculty:
Senior Director - Translational Ophthalmology & Research
Director - Clinical Development
Director - Clinical Development & Med Affairs
Senior Scientist I
Vice President & Global Head of Retina
“Looking forward to discussing with other drug developers how we can harness cutting-edge imaging technologies to improve endpoints in our clinical trials.”
Guillaume Normand, Director of Clinical Development, Novartis